Bicycle Therapeutics plc develops clinical-stage medicines based on its proprietary bicyclic peptide, or Bicycle®, technology. Its updates center on oncology programs using fully synthetic constrained peptides, including nuzefatide pevedotin, a Bicycle Drug Conjugate targeting EphA2; zelenectide pevedotin, a Bicycle Drug Conjugate targeting Nectin-4; BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist targeting Nectin-4 and CD137; and Bicycle Radioconjugates for radiopharmaceutical use.
Recurring news includes clinical and preclinical data presentations, oncology pipeline updates, financial results, leadership changes, and collaborations that support radioisotope and radiopharmaceutical supply. Company announcements also discuss work with partners in additional therapeutic areas and the structure of its U.K. and U.S. operations.
Summary not available.
Bicycle Therapeutics (NASDAQ: BCYC) has successfully completed its at-the-market (ATM) offering, raising gross proceeds of $50 million. Additionally, the company secured a $40 million term loan from Hercules Capital, with $30 million available at closing. These financings enhance Bicycle's financial stability as it progresses multiple clinical programs, including its lead candidate BT7480, slated for initiation next year. The company aims to achieve key clinical milestones in 2021, leveraging approximately $120 million raised in 2020, over half of which was non-dilutive.